Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05865535 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
A Phase 1 study of Cachexia, sponsored by AVEO Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 12
- Study locations
NCT05865535: Recruiting Phase 1 study of Cachexia, sponsored by AVEO Pharmaceuticals.
NCT05865535 is a Phase 1 study of Cachexia that is actively recruiting participants, run by AVEO Pharmaceuticals. The registered enrollment target is 30 participants, below the 200-participant average among 13 other Cachexia trials with a reported enrollment target (85% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05865535, a Phase 1 study of Cachexia, is actively recruiting participants, sponsored by AVEO Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 12
- Study locations
Study Summary
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Primary Outcome
AEs as characterized by incidence, type, frequency, and severity (graded according to National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\])
Conditions Studied
Interventions
- BIOLOGICAL AV-380
Study Locations (12)
California
- Beverly Hills Cancer Center - Beverly Hills
- Cancer and Blood Specialty Clinic - Lakewood
- Hoag Memorial Hospital - Newport Beach
Connecticut
- Hartford Hospital - Hartford
Florida
- Advent Health Orlando Hospital - Orlando
Nebraska
- Nebraska Cancer Specialists - Omaha
New Jersey
- Astera Cancer Care - East Brunswick
New York
- New York Cancer And Blood Specialists - Shirley
Oregon
- Oregon Health and Science University - Portland
South Carolina
- MUSC Hollings Cancer Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT05865535 shows while recruiting
NCT05865535 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 200-participant average among 13 other Cachexia trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Cachexia appearing as the primary indexed condition, and to 1 intervention - of which AV-380 is the first listed.
NCT05865535 lists 12 locations in 10 states (California, Connecticut, Florida).
Frequently Asked Questions
What is clinical trial NCT05865535 about?
NCT05865535 is a clinical study titled "A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia". This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiatio...
What is the current status of trial NCT05865535?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-06-13. Estimated completion is 2026-12-31.
What conditions does trial NCT05865535 study?
This clinical trial studies the following conditions: Cachexia.
What interventions are being tested in trial NCT05865535?
The interventions under investigation include: AV-380 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05865535?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05865535 being conducted?
This trial has 12 study locations across California, Connecticut, Florida, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cachexia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05865535's enrollment target sits among peer trials
30 10th of 13 higher than 4 of 13 other Cachexia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cachexia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
COMPLETED · Phase 1
-
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RECRUITING · Phase 2
-
Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma
RECRUITING
-
Ruxolitinib for Cancer Cachexia
ACTIVE NOT RECRUITING · Early Phase 1
-
Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI